Neurotech International Limited (ASX:NTI)

Market Cap	18.89M
Revenue (ttm)	2.44M
Net Income (ttm)	-10.60M
Shares Out	1.05B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,235
Average Volume	535,545
Open	0.0180
Previous Close	0.0170
Day's Range	0.0170 - 0.0190
52-Week Range	0.0120 - 0.0660
Beta	0.42
RSI	51.35
Earnings Date	Feb 24, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.